Related Experiment Video
Updated: Feb 16, 2026
Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence
Published on: November 2, 2014
A phase II study of apatinib in patients with recurrent epithelial ovarian cancer
Mingming Miao1, Guanming Deng1, Sujuan Luo1
1Department of Gynecologic Oncology, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, PR China.
Objective:
Antiangiogenic treatments have been implicated to play a major role in epithelial ovarian cancer (EOC). Apatinib, a novel oral antiangiogenic agent targeting vascular endothelial growth factor receptor (VEGFR2), is currently being studied in different tumor types and is already used in gastric adenocarcinoma. This study was performed to assess the efficacy and safety of apatinib in patients with recurrent, pretreated EOC.
Patients And Methods:
Patients with recurrent, platinum-resistant, pre-treated EOC who failed available standard chemotherapy were enrolled. Apatinib was administered as 500mg daily. Primary objective is the overall response rate (ORR) according to MASS criteria. Secondary objectives are progression free survival (PFS), overall survival (OS), disease control rate (DCR), safety and tolerability. The treatment duration is until disease progression or intolerability of apatinib.
Results:
29 eligible patients were enrolled in this multicenter, open-label, single arm study and received apatinib for a median of 36.8weeks (range 13-64.8weeks). Median follow-up time was 12months. 28 patients were eligible for efficacy analysis. ORR is 41.4% (95% confidence interval (CI), 23.3%-59.4%). DCR is 68.9% (95% CI, 52.1%-85.8%). Median PFS is 5.1months (95% CI, 3.8m-6.5m). Median OS is 14.5months (95% CI, 12.4m-16.4m). The most common treatment-related adverse events (AEs) were hand-foot syndrome (51.7%), hypertension (34.6%), nausea and vomiting (31.0%). 3 patients had no significant toxicity. 9 patients experienced grade 3 treatment-related AEs.
Conclusions:
Apatinib 500mg daily p.o. is a feasible treatment in patients with recurrent, platinum-resistant, pretreated EOC. Multi-center prospective studies enrolling more patients are needed.
Insights
Apatinib shows promise for recurrent epithelial ovarian cancer (EOC) patients, demonstrating a 41.4% overall response rate. This oral antiangiogenic therapy is a feasible option for platinum-resistant EOC, warranting further investigation.
Area of Science:
- Oncology
- Pharmacology
- Clinical Medicine
Background:
- Antiangiogenic therapies are crucial in epithelial ovarian cancer (EOC) treatment.
- Apatinib, a VEGFR2 inhibitor, is an oral antiangiogenic agent with existing use in gastric adenocarcinoma.
Purpose of the Study:
- To evaluate the efficacy and safety of apatinib in patients with recurrent, pretreated epithelial ovarian cancer (EOC).
- To assess overall response rate (ORR), progression-free survival (PFS), overall survival (OS), and disease control rate (DCR).
Main Methods:
- A multicenter, open-label, single-arm study enrolled 29 patients with recurrent, platinum-resistant EOC who had failed prior chemotherapy.
- Apatinib was administered orally at 500mg daily until disease progression or intolerance.
- Efficacy and safety endpoints, including ORR, PFS, OS, DCR, and adverse events, were monitored.
Main Results:
- The overall response rate (ORR) was 41.4% (95% CI, 23.3%-59.4%) with a disease control rate (DCR) of 68.9%.
- Median progression-free survival (PFS) was 5.1 months, and median overall survival (OS) was 14.5 months.
- Common adverse events included hand-foot syndrome (51.7%) and hypertension (34.6%); 9 patients experienced grade 3 AEs.
Conclusions:
- Apatinib 500mg daily is a feasible oral treatment option for patients with recurrent, platinum-resistant epithelial ovarian cancer.
- Further multi-center prospective studies with larger patient cohorts are recommended to confirm these findings.
